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DRUG THERAPY FOR ACUTE BLEEDING FROM PORTAL
HYPERTENSIVE GASTROPATHY
Panes, J., Pique, J.M., Bordas, J.M., Llach, J., Bosch, J., Teres, J. andRodes, J. (1994)
Reduction ofgastric hyperemia by glypress in andvasopressin administration in cirrhotic
patients withportalhypertensivegastropathy, Hepatololgy; 19." 55-60.
Gastric mucosal perfusion is increased in portal-hypertensive gastropathy, and this may
contribute to gastric bleeding from these lesions. Therefore drugs reducing gastric mucosal
perfusion may be beneficial in the treatment of overt bleeding from portal-hypertensive
gastropathy. In this study gastric mucosal perfusion was assessed in 28 cirrhotic patients with
portal-hypertensive gastropathy under basal conditions and after double-blind intravenous
administration of vasopressin (0.4 Ulmin), glypressin (2-mg injection) or placebo, with
laser-Doppler flowmetry and reflectance spectrophotometry. Vasopressin and glypressin
induced a significant increase in blood pressure and a decrease in heart rate, These effects were
more pronounced in the vasopressin group. Both vasopressin and glypressin induced a sustained
and similar reduction in gastric mucosal perfusion as assessed by laser-Doppler flowmetry
(-36% +8% and-34% + 6%, respectively; p < 0.05 with respect to basal values and with respect
to the control group). Whereas placebo had no effect. Both drugs significantly reduced the
oxygen content ofthe gastric mucosa; however, the impairment in mucosal oxygenation was
greater (p < 0.05) in the vasopressin group (-17% + 3%) than in the glypressin group
(-6% + 0.1%).We conclude that the increased gastric-perfusion in cirrhotic patients with portal-
hypertensive gastropathy may be reduced by either vasopressin or glypressin. These findings
support the use of these drugs in clinical trails treating bleeding portal-hypertensive
gastropathy. The lower reduction in gastric mucosal oxygen content observed with glypressin
could decrease the incidence ofischemic adverse events associated with the use ofvasopressin.
(HEPATOLOGY 1994; 19: 55-60.)
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PAPERDISCUSSION
Bleeding from esophageal varices and/or portal hyper-
tensive gastropathy(PHG) arecommon and lethal compli-
cations in patients with liver cirrhosis. In an attempt to
treat these complications of portal hypertension, many
investigators have been evaluating drugs which could de-
crease splanchnic blood flow and, thereby, reduce portal
flow and pressure. In the present paper, the authors inves-
tigate the effects ofvasopressin (VP) and glypressin(GLY)
on gastric mucosal oxygenation and perfusion in cirrhotic
patients withPHG by utilizingtwo endoscopic techniques,
reflectance spectophotometry (RS) and laser-doppler
flowmetry (LDF). The former gives an estimation ofthe
oxygen and hemoglobin content of the gastric mucosa,
and the latter estimates tissue perfusion. RS andLDF are
the techniques most widely used during endoscopy to
assess gastric mucosa perfusion. Although they are rela-
tively accurate they may be influenced by other factors,
including the number ofred blood cell circulating in the
gastric tissue and observer variability. Therefore, it is im-
portant to perform these studies under strict double blind
conditions.
VP is a powerful vasoconstrictor, which reduces blood
flow to the entire splanchnic territory. By this mechanism,
itcan reduce portal pressure and hepato-portal and collat-
eral blood flow. Nonetheless, VP is not without adverse
clinical effects namely those derived from vasoconstric-
tion of the systemic territory. Reduced coronary blood
flow, cardiac output and heart rate and increased systemic
vascular resistance are some ofthe hemodynamic changes
induced by VP that may restrict its use in up to 25% ofHPB INTERNATIONAL 211
patients. The association ofVP and Nitroglycerin (NGC)
enhances the reduction in portal pressure by reducing
hepato and portal-collateral resistance while attenuating
the systemic side effects ofVP. Therefore, ifVP is used,
it should always be associated withNGC.
Glypressin (GLY) is a syntheticVP analogue (triglycyl
lysine vasopressin or terlipressin) that is slowly converted
in vivo into VP by enzymatic cleavage of the triglycyl
residues. This slow transformation in tissues allows the
achievement ofhigh local concentrations with low circu-
lating levels (resulting in a lesser toxicity). The study per-
formed by Panes et al. demonstrates that cirrhotic patients
treated with VP or GLY have a significant increase in
arterial pressure and decrease in heart rate, gastric muco-
sal perfusion, gastric mucosal oxygen and hemoglobin
content in comparison with placebo. In this study, using
VPandGLY at the dosescommonly used in the treatment
ofvariceal bleeding, both drugs caused systemic hemody-
namic changes, although these effects were lessmarked in
theGLY group.
In the present study at the doses used, VP induced
significantly more systemic hemodynamic effects demon-
strated by a greater increase in arterial pressure and a
larger reduction in heart rate. However, locally in the
gastric mucosa, GLY seems to have a more marked vaso-
constrictive effect. This finding suggests a specific effect of
GLY in this regional bed. Surprisingly, this greater local
vasoconstrictive effect ofGLY is accompanied by a lesser
reduction in gastric mucosa oxygenation than the one
induced by VP. Perhaps, this is due to the detrimental
systemic effects ofVP which reduce Hb saturation. This
finding is ofpractical interest because it suggests thatGLY
should be used in preference to VP for bleeding PHG.
Clinical trials show thatGLY, incomparison to placebo
treatment, has a higher efficacy in controlling bleedingand
reducing mortality,5,6 and when compared withVP,GLY
shows significantly lower complications even whenNGC
is associated with VP. It is important to note that in the
study by Panes et al. the hemodynamic effects are ob-
served promptly after GLY administration. This point
lends support to the concept thatGLY may have a direct
vasoconstrictor effect by itself.
Somatostatin (SOM), another drug able to decrease
portal pressure by selectively vasoconstricting the
splanchnic circulation, may act through the inhibition of
splanchinic vasodilatory peptides. Because it has been
shown that vasoconstriction and reduction ofportal pres-
sure is more marked after i.v. bolus injection rather than
continuous infusion, it is recommended that during the
early hours oftreatment, a bolus administration be given
followed by a constant infusion. Actually, the authors of
the present paper recently reported that the increased
gastric perfusion that patients with liver cirrhosis and
PHG demonstrate can be effectively decreased by SOM.
The bolus injection caused a more pronounced reduction
in gastric perfusion than a constant infusion did, suggest-
ing a dose-related effect. The greatest advantage of this
drug seems to be the lack of side effects. Several trials
comparingSOM with other active treatments show that
SOM is highly effective in the treatment ofvariceal bleed-
ing, and it is truly a safe therapy.
Octreotide (OCT) is a cyclic octapeptide analogue of
SOM with the advantage ofa longer biological half-life.
Reports differ regarding the effect theOCT has on reduc-
ing portal pressure. Although it produces a reduction in
azygos, blood flow, this effect is no longer seen after one
hour, despite continuous infusion.Pretreatment withOCT
seems to ameliorate the increase in portal flow observed
after postprandial hyperemia. So far it is not clear, de-
spite several reports, what the real efficacy ofOCT is in
controlling gastrointestinal bleeding secondary to portal
hypertension. On this basis, studies with large number of
patients, clear end-points and different schedules oftreat-
ment comparing OCT with other effective therapies are
needed to assess definitive results.
In conclusion, by using endoscopic reflectance specto-
photometry and laser-doppler flowmetry, Panes et al.
demonstrate that bothVP andGLY are effective in reduc-
ing the increased gastric perfusion observed in cirrhotic
patients withPHG, providing evidence on applicability of
these endoscropic techniques. To characterize the effect
and theoretical advantages ofGLY over VP, or overVP
plus NGC, further studies are needed. Taking into
account the theoretical advantage ofless systemic hemo-
dynamic repercussions, although there are already pre-
liminary reports showing thatGLY andSOM are equally
effective in controlling bleeding,2 itwould be important to
perform appropriate controlled trials comparing GLY,
SOM andOCT.
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